Daewoong’s Nabota enters advanced market with Canadian approval

Published: 2018-08-22 17:46:53

Updated: 2018-08-22 17:46:53

Daewoong Pharmaceutical’s Nabota has finally opened a new pharmaceutically advanced market.

Daewoong Pharmaceutical(CEO Seung-Ho Jeon) announced its self-developed botulinum toxin product ‘Nabota’ was approved from the Health Canada on the 16^th. The Health Canada approved the Nabota’s indication for forehead wrinkles.

Thus, Nabota has become the first one to enter the Canadian market for the ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.